Halozyme Therapeutics EBITDA 2010-2024 | HALO

Halozyme Therapeutics EBITDA for the quarter ending September 30, 2024 was $0.182B, a 63.19% increase year-over-year.

  • Halozyme Therapeutics 2023 EBITDA was 0.423B, a 29.84% increase from 2022.
  • Halozyme Therapeutics 2022 EBITDA was 0.326B, a 14.51% increase from 2021.
  • Halozyme Therapeutics 2021 EBITDA was 0.285B, a 75.25% increase from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Halozyme Therapeutics EBITDA 2010-2024 | HALO

  • Halozyme Therapeutics 2023 EBITDA was 0.423B, a 29.84% increase from 2022.
  • Halozyme Therapeutics 2022 EBITDA was 0.326B, a 14.51% increase from 2021.
  • Halozyme Therapeutics 2021 EBITDA was 0.285B, a 75.25% increase from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.